Home
/
Gain Therapeutics, Inc.
/
Financials
/
Quarterly
Gain Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Gain Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2024
Sep 30, 2023
$55.2K
Nov 14, 2024
Q2
2024
Jun 30, 2023
$55.2K
Aug 8, 2024
Q1
2024
Mar 31, 2023
$55.2K
May 14, 2024
Q3
2023
Sep 30, 2022
$140.1K
Nov 14, 2023
Q2
2023
Jun 30, 2022
$95.1K
Aug 10, 2023
Q1
2023
Mar 31, 2022
$45.0K
May 12, 2023
Q3
2022
Sep 30, 2021
$27.3K
Nov 10, 2022
Q2
2022
Jun 30, 2021
$89.2K
Aug 8, 2022
Q1
2022
Mar 31, 2021
$5.3K
May 16, 2022
Q3
2021
Sep 30, 2020
$6.7K
Nov 12, 2021
Q2
2021
Jun 30, 2020
$6.4K
Aug 12, 2021
Q1
2021
Mar 31, 2020
$6.7K
May 10, 2021
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2024
Sep 30, 2023
$55.2K
Nov 14, 2024
Q2
2024
Jun 30, 2023
$55.2K
Aug 8, 2024
Q1
2024
Mar 31, 2023
$55.2K
May 14, 2024
Q3
2023
Sep 30, 2022
$132.6K
Nov 14, 2023
Q2
2023
Jun 30, 2022
$95.1K
Aug 10, 2023
Q1
2023
Mar 31, 2022
$37.5K
May 12, 2023
Q3
2022
Sep 30, 2021
$16.0K
Nov 10, 2022
Q2
2022
Jun 30, 2021
$81.6K
Aug 8, 2022
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($5.28M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($5.81M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($4.53M)
May 14, 2025
Q3
2025
Sep 30, 2024
($4.49M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($8.14M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($4.01M)
May 14, 2025
Q3
2024
Sep 30, 2023
($4.72M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($7.69M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($5.14M)
May 14, 2024
Q3
2023
Sep 30, 2022
($4.56M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($5.09M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($3.27M)
May 12, 2023
Q3
2022
Sep 30, 2021
($4.66M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($3.56M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($2.45M)
May 16, 2022
Q3
2021
Sep 30, 2020
($794.4K)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($543.4K)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($584.3K)
May 10, 2021
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($4.79M)
Nov 12, 2025
Q2
2025
Jun 30, 2025
($5.09M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($4.37M)
May 14, 2025
Q3
2025
Sep 30, 2024
($4.46M)
Nov 12, 2025
Q2
2025
Jun 30, 2024
($8.18M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($4.38M)
May 14, 2025
Q3
2024
Sep 30, 2023
($4.89M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($7.73M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($5.23M)
May 14, 2024
Q3
2023
Sep 30, 2022
($4.75M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($5.18M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($3.29M)
May 12, 2023
Q3
2022
Sep 30, 2021
($4.64M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($3.51M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($2.47M)
May 16, 2022
Q3
2021
Sep 30, 2020
($819.1K)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($532.5K)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($512.3K)
May 10, 2021